Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Durable remission in a patient of mixed phenotype acute leukemia with Philadelphia chromosome-positive treated with nilotinib and lenalidomide: A case report.

Medicine - 1 Apr 2018

Lai Binbin, Mu Qitian, Zhu Huiling, Wang Yi, Zhang Yi, Xu Kaihong, Sheng Lixia, Ouyang Guifang

Abstract excerpt

RATIONALE: Philadelphia chromosome-positive mixed phenotype acute leukemia (Ph+ MPAL) is a rare type of leukemia with poor prognosis. Tyrosine kinase inhibitors (TKIs) in combination with chemotherapy have significantly improved its remission rate. However, relapse remains the major obstacle to achieve long survival. Lenalidomide is a second-generation oral immunomodulatory drug that has been broadly applied in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Disease
Share to Induction Chemotherapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lenalidomide

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Maintenance Chemotherapy

Share to Philadelphia Chromosome

Share to Pyrimidines

Share to Thalidomide

Source

Open in PubMed Open full text

Identifiers

PMID: 29620650
DOI: 10.1097/MD.0000000000010294
PMCID: PMC5902271

Genes

BCR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Durable remission in a patient of mixed phenotype acute leukemia with Philadelphia chromosome-positive treated with nilotinib and lenalidomide: A case report.PMID 29620650Read ↗

Mixed-phenotype acute leukemia: state-of-the-art of the diagnosis, classification and treatment.Semantic proximity Read ↗

Mixed-phenotype acute leukemia: historical overview and a new definition.Semantic proximity Read ↗

Successful treatment of Philadelphia chromosome-positive mixed phenotype acute leukemia by appropriate alternation of second-generation tyrosine kinase inhibitors according to BCR-ABL1 mutation status.Semantic proximity Read ↗

[A study of mixed phenotype acute leukemia based on the 2008 World Health Organization classification].Semantic proximity Read ↗

An update on classification, genetics, and clinical approach to mixed phenotype acute leukemia (MPAL).Semantic proximity Read ↗

Clinical Characteristics and Diagnosis of Ph-Positive Mixed Phenotype Acute Leukemia.Semantic proximity Read ↗

Favorable response of a patient with primary B/myeloid mixed phenotype acute Leukemia to CD19-CAR-T: Case report and literature review.Semantic proximity Read ↗

Mixed phenotype acute leukemia: A study of 61 cases using World Health Organization and European Group for the Immunological Classification of Leukaemias criteria.Semantic proximity Read ↗

How I treat mixed-phenotype acute leukemiaSemantic proximity Read ↗

Exploring mixed phenotype acute leukemia: Clinical, immunophenotypic, cytogenetic, and prognostic insights from a tertiary care center.Semantic proximity Read ↗

Mixed-Phenotype Acute Leukemia: Diagnostic Criteria and PitfallsSemantic proximity Read ↗

Mixed-Phenotype Acute Leukemia: Clinical Diagnosis and Therapeutic StrategiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.